Brian Shinder, MD
Assistant ProfessorCards
About
Research
Publications
2025
Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer
Shinder B, Lee Y, Mao N, Salsabeel N, Zhang Z, Kaur H, Chen X, Chang Q, de Stanchina E, Gopalan A, Sawyers C, Carver B. Targeting Tumor Microenvironment–Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer. Molecular Cancer Therapeutics 2025, 25: 662-671. PMID: 41379983, PMCID: PMC13022569, DOI: 10.1158/1535-7163.mct-25-0505.Peer-Reviewed Original ResearchHarnessing the power of combination therapy: reflecting on the final survival data from the CLEAR study with lenvatinib plus pembrolizumab
Shinder B, Meng L, Singer E. Harnessing the power of combination therapy: reflecting on the final survival data from the CLEAR study with lenvatinib plus pembrolizumab. Translational Andrology And Urology 2025, 14: 2124128-2122128. PMID: 40949457, PMCID: PMC12433167, DOI: 10.21037/tau-2025-201.Commentaries, Editorials and Letters
2024
Chapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.Chapters
2023
Predictive Biomarkers in Advanced Renal Cell Carcinoma
Shinder B, Kronstedt S, Hakimi A. Predictive Biomarkers in Advanced Renal Cell Carcinoma. 2023, 251-268. DOI: 10.1007/978-3-031-40901-1_11.ChaptersChromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation
Lichtbroun B, Shinder B, Sara T, Srivastava A, Saraiya B, Mayer T, Cristelli R, Sadimin E, Weiss R, Singer E. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation. Journal Of Kidney Cancer 2023, 10: 1-8. PMID: 37441361, PMCID: PMC10334999, DOI: 10.15586/jkcvhl.v10i3.254.Peer-Reviewed Original ResearchFactors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original Research
2022
Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature
Cahill E, Tabakin A, Shinder B, Bramwit M, Saraiya B, Xu X, Salazar C, Zhou Z, Singer E. Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer 2022, 9: 32-38. PMID: 36118793, PMCID: PMC9431006, DOI: 10.15586/jkcvhl.v9i2.229.Peer-Reviewed Original ResearchRenal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature
Yoshitake S, Shinder B, Dazen K, Smith C, Mayer T, Sadimin E, Singer E. Renal Cell Carcinoma with Testicular Metastases: A Case Report and Review of the Literature. Journal Of Kidney Cancer 2022, 9: 22-26. PMID: 36118790, PMCID: PMC9430971, DOI: 10.15586/jkcvhl.v9i2.212.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFactors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original Research
2021
EDITORIAL COMMENT
Srivastava A, Shinder B, Singer E. EDITORIAL COMMENT. Urology 2021, 158: 115. PMID: 34895625, DOI: 10.1016/j.urology.2021.04.076.Commentaries, Editorials and Letters
Academic Achievements & Community Involvement
Clinical Care
Overview
Brian Shinder, MD, is a urologic oncologist who treats kidney, prostate, and bladder cancer.
Dr. Shinder says he was drawn to urology because of its variety, both in terms of conditions he treats and the types of procedures he performs. “It’s rewarding in that we can treat people and, in some cases, cure them of their disease, but also restore their function so that they can live better lives,” he says.
For most urologic diseases, surgery can be done either with a minimally invasive approach or through traditional, open surgery. “Both options have their place in treatment; it’s a matter of figuring out what is best for each patient based on their outcome and lifestyle goals,” Dr. Shinder says. “I make sure patients understand their options and help them decide the best way to move forward with their treatment.”
It's also an exciting time for the field, Dr. Shinder notes. “Urology has been at the forefront of robotic surgery. And the field continues to push boundaries regarding what can be done with robotic surgery,” he says. “There are also other, newer platforms and technologies to treat various diseases, including kidney stones and enlarged prostates. Urology has also been at the forefront of using genetics and different molecular markers to help diagnose conditions and decide the best treatment for patients.”
Clinical Specialties
Fact Sheets
Prostate Cancer
Learn More on Yale MedicineKidney Cancer
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- October 27, 2025
Yale Urology Research
- July 21, 2025
Multidisciplinary Prostate Cancer Clinic at Smilow Cancer Hospital at Stamford
- March 27, 2025
Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Greenwich
- July 30, 2024
Yale Urology Welcomes New Faculty
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.